Reviews/Probiotics and Gut Microbiome/Probiotic colonization of adult gut is transient
Microbiome · PGM-MICRO-01 · v2
When healthy adults take a probiotic, the added microbes are mostly detected only while they keep taking it and disappear within days of stopping. Several separate human studies in this corpus find the same pattern, whether they look at stool or at the gut wall [18][3][4][8]. But the same body of evidence shows this is not an iron rule: one strain of Bifidobacterium longum settled in and lasted at least six months in about 30% of people [1], and a Lactobacillus johnsonii strain kept turning up after people stopped eating it [11]. The panel concluded the statement is a reliable general description of what usually happens, but not something that holds for every strain or every person. That is why it landed as a strong default rather than an absolute certainty.
Independent adult-human studies converge on transience: candidate strains were detected only during the consumption period [18], persisted only about 3-6 days after intake stopped [3], produced a transient individualized effect on the gut mucosa [4], and attached only temporarily even when detectable beyond a week [8]. An in-vitro colon model similarly frames the benefit as reliance on transient engraftment [9]. The corpus also documents the boundaries of the rule: stable engraftment of B. longum AH1206 in 30% of adults for at least six months [1], and L. johnsonii 456 detectable beyond the initial ingestion period [11]. Dose raised how much and how long strains were recovered in feces but still within the intake-and-washout frame [5]. The contested point: The division is over whether 'is transient' can stand as categorical: [1] reports durable engraftment in a 30% minority for at least six months and [11] reports persistence beyond ingestion, both direct adult evidence against an absolute reading. A second axis is measurement — [8] warns that studying fecal samples alone is not sufficient to evaluate colonization, so stool-based transience may understate mucosal persistence.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Probiotics and Gut Microbiome, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The categorical wording 'is transient' is directly contradicted in a non-trivial minority: [1] reports stable engraftment in 30% of adults for >=6 months and [11] reports persistence beyond ingestion. The claim holds as a general rule, not an absolute.
'Colonization' is operationalized inconsistently across the corpus — fecal detection [3][18][19] vs mucosal attachment/engraftment [4][8]. [8] explicitly warns fecal sampling alone understates mucosal persistence, so transience measured in stool may overstate true clearance.
Where it remains uncertain. The same corpus documents durable exceptions — stable engraftment in 30% of adults for at least six months [1] and one strain persisting beyond ingestion [11] — so the rule is not absolute.
Aleatory
Persistence varies by individual — durable engraftment occurred in only 30% of adults in [1], and R0175 persisted >=15 days in only 6 of 13 intermediate-transit participants in [3].
Epistemic
The corpus documents strains that break the default ([1] AH1206; [11] L. johnsonii 456), but does not establish which strain or formulation properties predict durable versus transient behaviour.
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Quantifies short post-cessation persistence in healthy adults.
“persistence after intake cessation was not significantly different for R0052, HA-108, and HA-129 (~3-6 days)”
Panel auditInternal validity: medium · scope of inference: Post-cessation fecal persistence of five multispecies strains in healthy adults.Key limitations: pilot · open-label · fecal detection not mucosal · one strain persisted longer
Invasive human evidence that adult mucosal impact is transient.
“probiotics induced a transient, individualized impact on mucosal community structure and gut transcriptome”
Panel auditInternal validity: high · scope of inference: Mucosal colonization efficacy of an empiric multi-strain probiotic in healthy human adults.Key limitations: colonization was person-specific · no sample size in abstract · mucosal impact still occurred in some
Adult biopsy evidence: attachment temporary, with a short persistence tail.
“although the attachment was temporary, to remain for more than a week after discontinuation of GG administration”
Panel auditInternal validity: medium · scope of inference: Mucosal persistence of L. rhamnosus GG in human adult colon.Key limitations: small volunteer study · single strain · no N reported
States the general rule of transience in the adult gut.
“Bifidobacterium longum AH1206 stably persists in the gut of 30% of individuals for at least 6 months”
Panel auditInternal validity: medium · scope of inference: Durability of a single Bifidobacterium strain in healthy human adults conditioned on resident microbiome features.Key limitations: single strain · no total N · engraftment only in a minority
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct, independent adult evidence strongly supports transience as the norm, but corpus-internal exceptions of durable strain- and host-specific engraftment cap confidence below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Predictors of durable engraftment. Only [1] links persistence to resident-microbiome features; the corpus cannot say which strains or hosts will retain a probiotic. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Prospective adult cohort across multiple strains with pre-treatment metagenomic profiling and >=6-month follow-up, testing which baseline features predict engraftment.
Open question: Which strain and host features determine whether an ingested probiotic durably engrafts rather than clears? Why it is still open: Only [1] identifies predictors (low resident B. longum, underrepresented carbohydrate-utilization genes) for a single strain; no cross-strain rule exists in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19